Antitumor effect of D-erythrose in an abdominal metastatic model of colon carcinoma

Liu,Li‑Li; Yi,Tao; Zhao,Xia

doi:10.3892/ol.2014.2764

Antitumor effect of D-erythrose in an abdominal metastatic model of colon carcinoma

Authors:
- Li‑Li Liu
- Tao Yi
- Xia Zhao
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Key Laboratory of Obstetric, Gynecological and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: December 3, 2014 https://doi.org/10.3892/ol.2014.2764
Pages: 769-773

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Traditional chemotherapy drugs against colorectal cancer possess little or no specificity, leading to severe intolerable side‑effects. Therefore, it is necessary to develop additional specific therapeutic strategies. It has been suggested that D‑erythrose may specifically inhibit the growth of tumor cells. However, the in vivo antitumor effect of D‑erythrose against colorectal cancer remains unknown. Thus, the present study investigated the antitumor effect of D‑erythrose in an abdominal metastatic model of colon carcinoma. Intraperitoneal (IP) colon carcinoma‑bearing BALB/c mice received an IP injection of D‑erythrose or normal saline (NS) daily for 15 days. The mice were weighed every three days. The tumor weights and the volume of ascites were evaluated following the treatment. Terminal deoxynucleotidyl transferase‑mediated dUTP nick end labeling assay was used to assess apoptosis in tumor tissues. The results revealed that D‑erythrose significantly reduced the weight of the intraperitoneal tumor by 69.1%, markedly inhibited the development of ascites and increased tumor cell apoptosis, without any observed toxic effects. These observations suggest that D‑erythrose possesses antitumor activity against colon cancer. The present study may provide a potentially effective and specific approach for colon cancer treatment.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ojima I, Zuniga ES, Berger WT and Seitz JD: Tumor-targeting drug delivery of new-generation taxoids. Future Med Chem. 4:33–50. 2012. View Article : Google Scholar :
4	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
5	Schulz TJ, Thierbach R, Voigt A, et al: Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem. 281:977–981. 2006. View Article : Google Scholar
6	Zhao Y, Liu H, Riker AI, et al: Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed). 16:1844–1860. 2011. View Article : Google Scholar
7	Nagasawa H: Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment. J Pharmacol Sci. 115:446–452. 2011. View Article : Google Scholar : PubMed/NCBI
8	Chan DA, Sutphin PD, Nguyen P, et al: Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 3:94ra702011.PubMed/NCBI
9	Warburg O, Posener K and Negelein E: On metabolism of tumors. Biochem Z. 152:319–344. 1924.(In German).
10	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
11	Ristow M: Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care. 9:339–345. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 13:472–482. 2008. View Article : Google Scholar : PubMed/NCBI
13	Hsu PP and Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
14	Horecker BL: The pentose phosphate pathway. J Biol Chem. 277:47965–47971. 2002. View Article : Google Scholar : PubMed/NCBI
15	Hiatt HH and Horecker BL: D-erythrose metabolism in a strain of Alcaligenes faecalis. J Bacteriol. 71:649–654. 1956.PubMed/NCBI
16	Batt RD, Dickens F and Williamson DH: Tetrose metabolism 2. The utilization of tetroses and tetritols by rat tissues. Biochem J. 77:281–294. 1960.PubMed/NCBI
17	Wang X and Wei Y: Erythrose kill cancer cell in vitro and inhibit tumor growth in vivo. Cancer Res. 70(Suppl 1): 45482010. View Article : Google Scholar
18	Gou M, Men K, Zhang J, et al: Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. ACS Nano. 4:5573–5584. 2010. View Article : Google Scholar : PubMed/NCBI
19	Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885. 2005. View Article : Google Scholar : PubMed/NCBI
20	Jensen M, Engert A, Weissinger F, et al: Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs. 26:139–149. 2008. View Article : Google Scholar
21	Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL and Brouwers JR: Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 24:353–367. 2001. View Article : Google Scholar : PubMed/NCBI
22	National Industrial Chemicals Notification and Assessment Scheme (NICNAS). Full Public Report: Erythrulose (Erythrulose Pentapharm). http://www.nicnas.gov.au/__data/assets/pdf_file/0015/10338/SN19FR.pdf. Accessed February 11, 2008
23	Macdonald JS: Toxicity of 5-fluorouracil. Oncology (Williston Park). 13(7 Suppl 3): 33–34. 1999.
24	Alimonti A, Gelibter A, Pavese I, et al: New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev. 30:555–562. 2004. View Article : Google Scholar : PubMed/NCBI
25	Grothey A: Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 5(Suppl 1): S38–S46. 2005. View Article : Google Scholar : PubMed/NCBI
26	Hotta T, Takifuji K, Arii K, et al: Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. Oncol Rep. 14:433–439. 2005.PubMed/NCBI
27	Grenon NN and Chan J: Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses. Clin J Oncol Nurs. 13:285–296. 2009. View Article : Google Scholar : PubMed/NCBI